drugset / Trial / NCT01110356

Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age

NCT01110356

Phase 4 Completed 294 enrolled Vifor Pharma SGS S.A. · collab
RandomizedSingle-groupSingle-blindTreatment

Summary

research study of Ferric carboxymaltose to treat fatigue/exhaustion symptoms, believed to be due to iron deficiency.

Timeline

Start
2010-06
Primary completion
2011-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified 1000 mg Intravenous